Fractyl Health Common StockNASDAQ: GUTS

BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will report financial results for the third quarter 2024 and provide business updates on Tuesday, November 12, 2024, at 4:30 p.m. ET.

BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that it will present compelling weight maintenance data from both its Revita and Rejuva platforms at The Obesity Society's Annual Meeting at ObesityWeek 2024, held from November 2-6, 2024, in San Antonio, Texas.

BURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, and Dr. Timothy Kieffer, CSO of Fractyl Health, will participate in a virtual fireside chat at the upcoming Piper Sandler 2nd Annual Virtual Obesity Day on Wednesday, June 26, 2024 at 9:30 a.m.

Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025 Company expands Revita type 2 diabetes clinical study REVITALIZE-1, expanding eligibility; increases potential U.S. treatment population for Revita by over 6x (from ~4 to ~25 million patients) Company presented preclinical data showing greater, more durable weight loss for its GLP-1 pancreatic gene therapy Rejuva® vs. semaglutide in one of eight President Select Abstracts at the American Diabetes Association's 84 th Scientific Sessions BURLINGTON, Mass.

Fractyl Health, Inc. (NASDAQ: GUTS) Q1 2024 Earnings Conference Call on May 13, 2024 at 4:30 PM ET with Company Participants Stephen Jasper from Gilmartin Group, Harith Rajagopalan, Lisa Davidson, Timothy Kieffer, and Adrian Kimber. Conference Call Participants include Michael DiFiore from Evercore ISI and Michael Ulz from Morgan Stanley. The Operator welcomes everyone to Fractyl Health's First Quarter Financial Results and Business Updates Call, which is being recorded.

Volatile stocks are essential for short-term traders, as they offer the potential to profit in both upward and downward movements. Identifying the most volatile stocks is key for day traders and swing traders to capitalize on quick cash opportunities.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Shares of Fractyl Health fell 8.3% on their market debut on Friday, giving the obesity and diabetes drug developer a market capitalization of $654.6 million.

Obesity and diabetes drug developer Fractyl Health on Thursday priced its U.S. initial public offering (IPO) below an indicated range to raise $110 million.